trending Market Intelligence /marketintelligence/en/news-insights/trending/ukyiT9GJevhOy900bKxCfA2 content esgSubNav
In This List

Tracon Pharmaceuticals to sell $15M of common shares to private fund

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Tracon Pharmaceuticals to sell $15M of common shares to private fund

Tracon Pharmaceuticals Inc. agreed to sell common shares for up to $15 million to Chicago-based private fund Aspire Capital Fund LLC over a period of 30 months.

San Diego-based biotechnology company Tracon issued 1,426,579 common shares to the asset management firm as consideration for entering into the agreement.

Tracon plans to use the proceeds to advance its potential drugs pipeline and product development platform. Funds will also be used for general corporate purposes.

Under the agreement, Tracon will be eligible to make requests to Aspire Capital for the purchase of shares. Moreover, Aspire Capital cannot ask Tracon to sell any shares.

Tracon holds the right to terminate the agreement at any time without any additional cost or penalty.